Purity, Identity, Quantity, Sterility and Endotoxin: Five Different Quality Questions
The short answer
Purity, identity, quantity, sterility and endotoxin are separate quality questions. A material can perform well on one attribute and fail another. For example, a chromatogram dominated by one peak does not demonstrate the absence of viable microorganisms or bacterial endotoxins.
Responsible interpretation keeps each result attached to the method, sample and specification it addresses.
Identity: is it the expected molecule?
Identity testing asks whether the material is consistent with the claimed chemical entity. For a peptide, evidence may include accurate molecular mass, chromatographic comparison, amino-acid or sequence-related analysis and other orthogonal techniques. Identity is not established merely because the material has a high main-peak area.
Purity: what else is detected?
Purity testing evaluates related substances and other components that a defined method can detect and separate. Peptide impurities can include deletion sequences, truncations, oxidation products, deamidated forms, aggregates or synthesis-related residues. A purity result is bounded by method specificity, detection response and integration choices.
Quantity: how much target material is present?
Quantity or assay asks how much target analyte is present. This may require a calibrated quantitative method and a suitable reference standard. Fill mass, net vial mass and HPLC area percentage are not interchangeable with peptide assay. Water and counter-ions can affect gravimetric totals.
Sterility: are viable microorganisms absent under the test?
Sterility testing is a microbiological examination performed under controlled conditions. It is not inferred from chemical purity, visual clarity, filtration claims or the absence of obvious contamination. Sterility assurance also depends on manufacturing controls, validated processes and container-closure integrity; a finished-product test samples only part of a lot.
Endotoxin: a different microbial hazard
Bacterial endotoxins are lipopolysaccharide components associated with Gram-negative bacteria. A sample can contain no viable bacteria yet still contain endotoxin, because endotoxin can remain after bacterial death. Endotoxin testing therefore answers a different question from sterility testing.
Why a “99% pure” statement is incomplete
Without the method and context, a headline purity percentage can be misunderstood. It does not show the identity of the main peak, total peptide content, microbial status, endotoxin level, residual solvent profile, counter-ion content or suitability for a particular use.
A stronger quality record uses a panel of appropriately validated methods and reports each attribute separately.
Key points
- Identity asks what the molecule is.
- Purity asks what related components a method detects.
- Quantity asks how much target material is present.
- Sterility addresses viable microorganisms.
- Endotoxin testing addresses bacterial lipopolysaccharide.
- None of these five results substitutes for the others.
What this article does not establish
This article does not certify any product or lot and does not establish sterility, endotoxin compliance, safety, effectiveness or suitability for human use.
References
- U.S. Food and Drug Administration. Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice
- U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers
- International Council for Harmonisation. Q6A: Specifications—Test Procedures and Acceptance Criteria. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products
- International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2r2-validation-analytical-procedures